tradingview.com
Cure8 news brief
Why This Matters
FDA approval and label updates for Skyrizi may affect treatment options and prescribing for adults with moderate-to-severe Crohn’s disease. AbbVie’s trial and acquisition news signals potential future therapies entering the immunology pipeline.
Who Should Pay Attention
Adult patients with Crohn’s disease; clinicians treating IBD; patients on biologic therapies; researchers and investors tracking drug development.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
Skyrizi (risankizumab) was reported as FDA-approved for subcutaneous induction in adults with moderate-to-severe Crohn’s disease, and AbbVie filed for EMA approval. The article also notes a label update mentioning tuberculosis (TB) testing. AbbVie announced Phase 3
Keep In Mind
Article is a corporate/market summary (TradingView) citing AbbVie/PR Newswire/Reuters; it summarizes approvals, filings, trial success, and an acquisition without detailed clinical results. Verify with AbbVie press releases or regulatory documents.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 31, 2026, 7:38 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
What AbbVie (ABBV) Said on Its Q3 Earnings Call - TradingView
New U.S. approval and company plans for SKYRIZI in Crohn’s disease could affect treatment options, prescribing patterns, and access timelines. Patients on or considering biologics may see changes in availability or new...
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
Crohn's Disease Therapeutics Market is Expected to Reach USD - openPR.com
Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.